PRESENTATION
SMC Laboratories is highly regarded worldwide as a consulting CRO that designs studies in line with the demands of pharmaceutical companies and research institutions.
In particular, in the NASH-HCC field, SMC is a highly regarded CRO, because of our unique STAM™ mice.
The results achieved with our STAM™ have been introduced in academic publications as well as scientific conferences.
Presentations
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 3000
No.55
First EASL NAFLD Summit 2017,
“Dual CCR2/5 antagonist decreases hepatic inflammation in acute liver injury and NASH metabolic animal models” Pfizer Inc.
No.54
First EASL NAFLD Summit 2017,
“AXA1125, a novel defined amino acid composition (DAAC), improves NAFLD activity score (NAS) and reduces fibrosis in two rodent models of nonalcoholic steathepatitis (NASH)” Axcella Health, Inc.
No.53
AASLD 2017,
“The Anti-Fibrogenic and Liver Protective Effects of Namodenoson (CF102) in a Non-Alcoholic Steatohepatitis Model” Can-Fite BioPharma Ltd.
No.52
AASLD 2017,
“DPP4 Inhibitor Suppressed Progression of NASH-related Hepatocellular Carcinoma with Inhibition of Metabolic Reprograming in p62-Keap 1-Nrf2-pentose Phosphate Pathway in a Mouse Model: A Metabolomic Analysis” Kurume University School of Medicine
No.51
AASLD 2017,
“CB4209 and CB4211 Reduce the NAFLD Activity Score in the STAM™ Model of NASH, Reduce Triglyceride Levels, and Induce Selective Fat Mass Loss in DIO Mice” CohBar, Inc.
No.50
AASLD 2017,
“Combination Treatment of LJN452 and Cenicriviroc Snows Additive Effects in a Diet-Induced NASH Model” Genomics Institute of the Novartis Research Foundation/Allergan plc/Novartis Institutes for BioMedical Research, Inc.
No.49
AASLD 2017,
“Gemcabene Attenuates the NAFLD Activity and Fibrosis Scores, and Downregulates Hepatic Inflammatory Genes in the STAM™ Murine Model of NASH-HCC” Gemphire Therapeutics Inc.
No.48
DDW 2017,
“A HMG-CoA Reductase Inhibitor, Rosuvastatin, as a Potential Preventive Drug for The Development of Hepatocellular Carcinoma Associated With Non-alcoholic Fatty Liver Disease in Mice” Osaka Medical College
No.47
EASL the International Liver CongressTM 2017,
“Anti-fibrotic effect of NV556,a sanglifehrin-based cyclophilin inhibitor,in a preclinical model of non-alcoholic steatohepatitis” Neuro Vive Pharmaceutical AB
No.46
AACR 2017,
“Inhibition of gene expression during non-alcoholic steatohepatitis (NASH)-related hepatocarcinogenesis is mediated by histone H4 lysine 16 deacetylation” FDA-National Center for Toxicological Research.
No.45
AACR 2017,
“Alterations in the chromatin accessibility in nonalcoholic steatohepatitis-associated hepatocellular carcinoma” FDA-National Center for Toxicological Research
No.44
AACR 2017,
“Role of miRNAome deregulation in the pathogenesis of non-alcoholic steatohepatitis (NASH)-derived hepatocellular carcinoma” FDA-National Center for Toxicological Research
No.43
AASLD 2017,
Emerging Trends Conference: Emerging Trends in Non-Alcoholic Fatty Liver Disease, “The Novel Antidiabetic Candidate MTBL0036 Greatly Diminishes The NAFLD Activity Score in The STAM™ Mouse Model of NASH” Metabolys Inc.
No.42
AASLD 2017,
Emerging Trends Conference: Emerging Trends in Non-Alcoholic Fatty Liver Disease, “DUR-928, An Endogenous Regulatory Molecule, Exhibits Anti-Inflammatory and Antifibrotic Activity in a Mouse Model of NASH” DURECT Corporation